Achaogen

Achaogen is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of innovative antibacterials to treat multi-drug resistant (MDR), gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including CRE. Achaogen is also developing an oral antibacterial candidate, C-Scape, a combination of an approved beta-lactam and an approved beta-lactamase inhibitor with the potential to treat patients with complicated urinary tract infections (cUTI) due to MDR pathogens. Achaogen's research and development pipeline includes additional gram-negative programs such as inhibitors of LpxC, an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program.

Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
2004
Size (employees)
106 (est)+71%
Achaogen was founded in 2004 and is headquartered in South San Francisco, US

Achaogen Office Locations

Achaogen has an office in South San Francisco
South San Francisco, US (HQ)
371 7000 Shoreline Ct

Achaogen Data and Metrics

Achaogen Financial Metrics

Achaogen's revenue was reported to be $7.5 m in Q1, 2017
USD

Revenue (Q1, 2017)

7.5 m

Net income (Q1, 2017)

(33.3 m)

EBIT (Q1, 2017)

(17.9 m)

Market capitalization (22-Aug-2017)

737.7 m

Cash (31-Mar-2017)

37.6 m
Achaogen's current market capitalization is $737.7 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

20 m26.1 m41.8 m

Revenue growth, %

31%60%

R&D expense

30.1 m40.2 m74 m

General and administrative expense

9.6 m12.4 m17.1 m

Operating expense total

39.8 m52.6 m91.1 m

EBIT

(19.8 m)(26.6 m)(49.3 m)

EBIT margin, %

(99%)(102%)(118%)

Interest expense

397 k699 k2.3 m

Net Income

(20.2 m)(27.1 m)(71.2 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

5.2 m4.5 m4.9 m12 m4.5 m5.8 m9.1 m16 m7.5 m

R&D expense

6.2 m10.7 m7.9 m10.1 m10 m13.9 m21.7 m20.5 m18.6 m

General and administrative expense

2.3 m2.2 m3.2 m2.9 m3 m3.8 m4 m4.5 m6.8 m

Operating expense total

8.5 m12.9 m11.1 m13 m13 m17.7 m25.7 m25 m25.3 m

EBIT

(3.3 m)(8.3 m)(6.2 m)(929 k)(8.5 m)(11.8 m)(16.5 m)(9 m)(17.9 m)

EBIT margin, %

(64%)(184%)(128%)(8%)(191%)(202%)(181%)(56%)(240%)

Interest expense

217 k264 k438 k447 k670 k706 k

Net Income

(8.3 m)(6.2 m)(886 k)(8.8 m)(12.2 m)(18.3 m)(11 m)(33.3 m)
USDFY, 2014FY, 2015FY, 2016

Cash

18.9 m20.3 m119 m

Accounts Receivable

301 k

Inventories

210.1 m

Current Assets

69.4 m65.5 m160.3 m

PP&E

725 k905 k3.3 m

Total Assets

70.3 m66.9 m163.9 m

Accounts Payable

2.1 m3.5 m5.7 m

Current Liabilities

5.5 m8.7 m19.7 m

Total Liabilities

57.2 m

Additional Paid-in Capital

213.5 m219.2 m353.9 m

Retained Earnings

(148.9 m)(176 m)(247.2 m)

Total Equity

43.2 m106.7 m

Financial Leverage

1.5 x1.5 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

74.5 m46.9 m22.9 m39.5 m35.1 m19.4 m54.6 m41.8 m37.6 m

Current Assets

80.4 m76.6 m66.7 m66.6 m76.1 m57.9 m81.3 m79.4 m147.1 m

PP&E

615 k662 k648 k902 k836 k1.1 m995 k1 m8.4 m

Total Assets

81.2 m77.4 m67.5 m67.7 m77.4 m59.2 m82.3 m80.7 m155.8 m

Accounts Payable

2.6 m6.2 m3.9 m4 m5.3 m6.6 m6.1 m7.6 m11.6 m

Current Liabilities

5.2 m9 m7.3 m7.3 m8.8 m12.7 m15.7 m19.8 m25.4 m

Additional Paid-in Capital

211.6 m212.2 m215.1 m216.2 m218.3 m220 m243.9 m248.5 m359.1 m

Retained Earnings

(135.7 m)(144 m)(155.1 m)(156 m)(164.7 m)(188.2 m)(206.5 m)(217.5 m)(280.5 m)

Total Equity

75.8 m68.2 m60.3 m53.6 m31.8 m37.5 m31 m78.6 m

Financial Leverage

1.1 x1.1 x1.1 x1.4 x1.9 x2.2 x2.6 x2 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(20.2 m)(27.1 m)(71.2 m)

Depreciation and Amortization

358 k426 k441 k

Cash From Operating Activities

8.1 m1.4 m(46.9 m)

Purchases of PP&E

(340 k)(606 k)(901 k)

Cash From Investing Activities

(45.4 m)5.2 m10.4 m

Cash From Financing Activities

67.9 m17.3 m135.5 m

Interest Paid

221 k396 k1.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(8.3 m)(6.2 m)(886 k)(8.8 m)(12.2 m)(18.3 m)(11 m)(33.3 m)

Accounts Payable

2.6 m6.2 m3.9 m4 m5.3 m6.6 m6.1 m7.6 m11.6 m
USDY, 2017

Revenue/Employee

88.8 k

Financial Leverage

2 x

Achaogen Market Value History

Traffic Overview of Achaogen

Achaogen Online and Social Media Presence

Achaogen Company Life and Culture

You may also be interested in